In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Ajinomoto combines two biotech ingredients in futuristic latte
In Singapore, iced lattes made from beanless coffee and cow-free proteins pulled from air will be available shortly in a preview at the country’s...
San Fran hotspot Fiorella hosts Mission Barns’ first cultivated pork sale
In California, cultivated meat maker Mission Barns has sold its pork for the first time at an exclusive dinner at San Francisco hot spot...
Uluu raises $10.4M to scale seaweed-based plastic
In Australia, seaweed-based plastic startup Uluu has raised AU$16 million (US$10.4 million) to build a demonstration plant to prove the viability of its technology.
Uluu’s...